Triple-negative breast cancer, which is defined by a lack of expression of the estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) receptors, represents approximately 10–15% of all breast cancers and is characterized by more aggressive tumor growth, poorer differentiation, and a higher proliferation index (Ki-67), as well as the associated unfavorable prognosis [1]. The gene discussed is MKI67; the disease is neoplasm.